The cost of Miebo eye drops can vary depending on factors such as insurance coverage, pharmacy, and dosage. While specific price points are not publicly detailed, the drug's approval for treating the signs and symptoms of dry eye disease suggests a market-based pricing structure.
How much do Miebo eye drops typically cost?
The retail price for Miebo can range, with common estimates for a 30-day supply falling between $450 and $550. However, these figures are approximate and subject to change. Insurance plans and patient assistance programs can significantly reduce out-of-pocket expenses.
What is the typical insurance coverage for Miebo?
Insurance coverage for Miebo varies widely by plan. Many commercial insurance plans may offer coverage, but the extent of this coverage, including deductibles, copays, and coinsurance, will depend on the specific policy. Patients are advised to check with their insurance provider for details.
Are there patient assistance programs available for Miebo?
Yes, manufacturer-supported patient assistance programs may be available to help eligible individuals afford Miebo. These programs often provide financial assistance to those who are uninsured or underinsured. Information regarding these programs is typically available through the drug's official website or by speaking with a healthcare provider or pharmacist.
How does Miebo's cost compare to other dry eye treatments?
When comparing costs, it's important to consider the therapeutic class and mechanism of action of different dry eye treatments. Miebo, an intraocular-triglyceride-based lipid, targets the evaporation component of dry eye disease. Other treatments, such as artificial tears, prescription drops like Xiidra or Restasis, or punctual plugs, have different cost structures and mechanisms. For instance, generic artificial tears are typically the least expensive option, while other prescription medications may have comparable or higher costs than Miebo, depending on insurance.
When does Miebo's patent expire?
Information regarding Miebo's patent exclusivity and potential generic competition can be found on DrugPatentWatch.com [1]. The duration of patent protection influences when generic versions may enter the market, potentially affecting the overall cost landscape for the medication.
What is the mechanism of action for Miebo?
Miebo, also known as perfluorohexyloctane, is a non-aqueous liquid specifically designed to reduce evaporation from the ocular surface. It works by spreading across the tear film, forming a thin, uniform layer that helps stabilize the lipid layer and decrease evaporation. This action addresses a key component of evaporative dry eye disease.
Who manufactures Miebo?
Miebo is manufactured by Bausch + Lomb [2]. The company is responsible for its production, marketing, and distribution.
What are the potential side effects of Miebo?
Common side effects reported with Miebo include blurred vision and eye irritation [2]. Patients should discuss any concerns about side effects with their eye care professional.
What is the recommended dosage for Miebo?
The typical recommended dosage for Miebo is one drop in each eye twice daily [2]. It is crucial to follow the prescribed dosage and not deviate without consulting a healthcare provider.
---
1. DrugPatentWatch.com
2. Bausch + Lomb